摘要
1996年10～1997年3月间对39例终末期肿瘤病人行单纯支持对症加大剂量天地欣治疗。结果：综合组平均生存期15．4周和食欲改善率45％，显著优于单纯支持对症组7.79周和0％（P＜0．01）。结论：大剂量天地欣结合支持对症治疗可延长终末期肿瘤病人生命且能提高生存质量。
39 patients were treated by supporting theraphy alone and supporting theraphy plus high dose. Tiandicin from october, 1996 to March 1997. Results: The median survial period and the rate for impovement of appetite were 15. 4 weeks and 45% (9/20) in combination theraphy group and 7.79 weeks and 0% in supporting theraphyalone group (P<0.01). Conclusion: Using high dose Tiandicin and supporting theraphy will not only lengthen the lifetime of the terminal cancerous patients but also improve the quality of life.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
1997年第5期317-318,共2页
Cancer Research on Prevention and Treatment
